CHMP’s December opinions include restrictions for Veklury in COVID, support for Daiichi, Seagen breast cancer drugs

In its December opinions, EMA’s CHMP recommended a restriction for Gilead’s Veklury, specifying that COVID-19 patients should be on low- or high-flow oxygen or other non-invasive ventilation at the start of treatment. 

The committee also backed Enhertu trastuzumab deruxtecan from  Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Tukysa tucatinib from Seagen Inc. (NASDAQ:SGEN), both to treat HER2-positive breast cancer; and Lumoxiti moxetumomab pasudotox from  AstraZeneca plc (LSE:AZN; NASDAQ:AZN) for relapsed or refractory hairy cell leukemia...